![]() Monitor to discover how your customers are using their mobiles and integrate your apps into these habits simplifying people’s lives.But let them solve their problems intuitively and effortlessly. Help users and solve their problems. Find an idea to implement in a mobile app that would solve business problems your clients face.An app should be a real extension of the brand. The idea behind your app with a clear correlation between it and your company will first satisfy your marketing and PR goals.Look at mobility as a new landscape of communication with customers. Like user experience, it is about the user, not about your ambitions or personal goals.Here are our observations of what successful mobile apps should for business entail So, what are the magic secrets of incredibly successful competition with more than 1.5 million other apps in either Apple’s or Google’s app stores? In today’s article, we will take a look at the mobile success stories of famous brands and discuss why your business needs a mobile app. This has led to a change in our practice toward offering PBT as the first-line treatment for these patients.īrachytherapy COB plaque Juxtapapillary choroidal melanoma Notched plaque Ruthenium-106.Mobile apps offer numerous opportunities for businesses of different shapes and sizes, from startups to enterprises. But it’s not enough to just create and launch a branded app to boost your sales and customer relations. Juxtapapillary choroidal melanomas treated with notched ruthenium plaques have a high recurrence rate and frequently need salvage treatment with PBT for tumour control. ![]() The observed risk of recurrence over 5 years was 31% (95% CI: 14.1%, 47.8%), and the risk of enucleation over 5 years was 11.5% (95% CI: 0.9%, 21.8%). Complications included maculopathy (10%), retinal detachment (5%), neovascular glaucoma (2.5%), and diplopia (2.5%). Six of these were treated with salvage proton beam therapy (PBT), 2 with transpupillary thermotherapy followed by PBT, and 5 with enucleation. Over the maximum follow-up time, 13 tumours (32.5%) recurred. The median follow-up was 51 months (14-100 months). The mean presenting vision was 0.3 logMAR, and the mean final vision was 0.7 logMAR, with 62.5% retaining >1.0 logMAR and 50% retaining >0.3 logMAR at the final follow-up. AJCC tumour category distribution was 62.5% T1, 32.5% T2, and 5% T3 tumours. We reviewed 40 patients with a median tumour diameter of 8.4 mm (range 5-17 mm) and a median thickness of 2.5 mm (range 1.1-6 mm). The data were analysed with respect to various outcome measures including recurrence, complications, vision, and eye preservation. Juxtapapillary choroidal melanomas (tumours within 2 disc diameters from the optic disc) treated with notched ruthenium-106 plaques (Eckert & Ziegler, BEBIG, Berlin, Germany) at the Scottish Ocular Oncology Service between 20 were retrospectively reviewed. This study aimed to evaluate the outcomes of juxtapapillary choroidal melanomas treated with notched ruthenium-106 plaques.
0 Comments
Leave a Reply. |